DLL3/CD70 dual CAR T

DLL3/CD70 dual CAR T is a preclinical, next-generation, off-the-shelf (allogeneic) chimeric antigen receptor (CAR) T-cell therapy candidate being developed by Allogene Therapeutics. Designed for the treatment of small cell lung cancer (SCLC) and other neuroendocrine tumors, this cell-based immunotherapy pairs a CAR targeting delta-like ligand 3 (DLL3) with a CAR targeting CD70. The DLL3 CAR is directed against the tumor antigen, while the CD70 CAR is engineered using Allogene's proprietary Dagger® technology to enhance resistance to host immune-mediated rejection, thereby prolonging CAR T-cell persistence. The candidate is manufactured using optimized site-specific integration to improve tumor control and cell performance.